226 related articles for article (PubMed ID: 31954773)
1. mGlu2/3 receptor antagonism: A mechanism to induce rapid antidepressant effects without ketamine-associated side-effects.
Witkin JM
Pharmacol Biochem Behav; 2020 Mar; 190():172854. PubMed ID: 31954773
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive
Witkin JM; Mitchell SN; Wafford KA; Carter G; Gilmour G; Li J; Eastwood BJ; Overshiner C; Li X; Rorick-Kehn L; Rasmussen K; Anderson WH; Nikolayev A; Tolstikov VV; Kuo MS; Catlow JT; Li R; Smith SC; Mitch CH; Ornstein PL; Swanson S; Monn JA
J Pharmacol Exp Ther; 2017 Apr; 361(1):68-86. PubMed ID: 28138040
[TBL] [Abstract][Full Text] [Related]
3. Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effects.
Witkin JM; Monn JA; Li J; Johnson B; McKinzie DL; Wang XS; Heinz BA; Li R; Ornstein PL; Smith SC; Mitch CH; Calligaro DO; Swanson S; Allen D; Phillips K; Gilmour G
Pharmacol Biochem Behav; 2017 Apr; 155():43-55. PubMed ID: 28285123
[TBL] [Abstract][Full Text] [Related]
4. The group II mGlu receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL/6J mice.
Pałucha-Poniewiera A; Podkowa K; Rafało-Ulińska A
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110239. PubMed ID: 33400944
[TBL] [Abstract][Full Text] [Related]
5. mGlu2/3 receptor as a novel target for rapid acting antidepressants.
Chaki S
Adv Pharmacol; 2020; 89():289-309. PubMed ID: 32616210
[TBL] [Abstract][Full Text] [Related]
6. The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits.
Witkin JM; Monn JA; Schoepp DD; Li X; Overshiner C; Mitchell SN; Carter G; Johnson B; Rasmussen K; Rorick-Kehn LM
J Pharmacol Exp Ther; 2016 Jul; 358(1):71-82. PubMed ID: 27189960
[TBL] [Abstract][Full Text] [Related]
7. mGlu2/3 receptor antagonists.
Chaki S
Adv Pharmacol; 2019; 86():97-120. PubMed ID: 31378257
[TBL] [Abstract][Full Text] [Related]
8. Role of Serotonergic System in the Antidepressant Actions of mGlu2/3 Receptor Antagonists: Similarity to Ketamine.
Chaki S; Fukumoto K
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30871246
[TBL] [Abstract][Full Text] [Related]
9. The role of mGlu
Pałucha-Poniewiera A
Pharmacol Biochem Behav; 2022 Oct; 220():173454. PubMed ID: 36038006
[TBL] [Abstract][Full Text] [Related]
10. [The potential of group II metabotropic glutamate receptor antagonists as a novel antidepressant].
Chaki S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Aug; 32(4):219-26. PubMed ID: 23012890
[TBL] [Abstract][Full Text] [Related]
11. (
Zanos P; Highland JN; Stewart BW; Georgiou P; Jenne CE; Lovett J; Morris PJ; Thomas CJ; Moaddel R; Zarate CA; Gould TD
Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6441-6450. PubMed ID: 30867285
[TBL] [Abstract][Full Text] [Related]
12. mGlu2/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development.
Chaki S; Watanabe M
Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1451-1462. PubMed ID: 36715750
[TBL] [Abstract][Full Text] [Related]
13. Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists.
Koike H; Iijima M; Chaki S
Neuropharmacology; 2011 Dec; 61(8):1419-23. PubMed ID: 21903115
[TBL] [Abstract][Full Text] [Related]
14. Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats.
Koike H; Chaki S
Behav Brain Res; 2014 Sep; 271():111-5. PubMed ID: 24909673
[TBL] [Abstract][Full Text] [Related]
15. mGlu2/3 Receptor Antagonists as Novel Antidepressants.
Chaki S
Trends Pharmacol Sci; 2017 Jun; 38(6):569-580. PubMed ID: 28413097
[TBL] [Abstract][Full Text] [Related]
16. Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery.
Musazzi L
Expert Opin Drug Discov; 2021 Feb; 16(2):147-157. PubMed ID: 32962432
[TBL] [Abstract][Full Text] [Related]
17. Role of group II metabotropic glutamate receptors in ketamine's antidepressant actions.
Onisiforou A; Georgiou P; Zanos P
Pharmacol Biochem Behav; 2023 Feb; 223():173531. PubMed ID: 36841543
[TBL] [Abstract][Full Text] [Related]
18. Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice.
Ago Y; Yano K; Araki R; Hiramatsu N; Kita Y; Kawasaki T; Onoe H; Chaki S; Nakazato A; Hashimoto H; Baba A; Takuma K; Matsuda T
Neuropharmacology; 2013 Feb; 65():29-38. PubMed ID: 23022081
[TBL] [Abstract][Full Text] [Related]
19. In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu
Witkin JM; Ornstein PL; Mitch CH; Li R; Smith SC; Heinz BA; Wang XS; Xiang C; Carter JH; Anderson WH; Li X; Broad LM; Pasqui F; Fitzjohn SM; Sanger HE; Smith JL; Catlow J; Swanson S; Monn JA
Neuropharmacology; 2017 Mar; 115():100-114. PubMed ID: 26748052
[TBL] [Abstract][Full Text] [Related]
20. Antidepressant-like actions of the mGlu2/3 receptor antagonist TP0178894 in the chronic social defeat stress model: Comparison with escitalopram.
Dong C; Tian Z; Fujita Y; Fujita A; Hino N; Iijima M; Hashimoto K
Pharmacol Biochem Behav; 2022 Jan; 212():173316. PubMed ID: 34968554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
